Medicine
Proleukin 1.1 mg/mL powder for injection
Proleukin 1.1 mg/mL powder for injection is a prescription medicine containing Aldesleukin for intravenous use, marketed by Iovance Biotherapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store unopened vials refrigerated at 2° to 8°C (36° to 46°F) in the original…
Key facts
- Active ingredient (INN)
- Aldesleukin
- Brand
- Proleukin
- Strength
- 1.1 mg/mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Iovance Biotherapeutics
- Manufacturer
- Iovance Biotherapeutics
- Origin register
- US FDA, United States
- Storage
- Store unopened vials refrigerated at 2° to 8°C (36° to 46°F) in the original carton to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L03AC01 Aldesleukin
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 May 1992
- Identifiers
- RxCUI 105648, 307816DailyMed set ID f3c516ad-d405-4fbe-af6a-962080dbfa7dNDC 73776-022Application BLA103293
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose | 73776-022-01 | Iovance Biotherapeutics | 15 July 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 May 1992 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Aldesleukin is a lymphocyte growth factor indicated for the treatment of adults with metastatic renal cell carcinoma, among other approved uses. It is available as powder for injection for intravenous use. MedsAcross supplies Aldesleukin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AldesleukinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- PROLEUKIN prescribing information (Iovance Biotherapeutics) · U.S. National Library of Medicine, DailyMed
Need Proleukin 1.1 mg/mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.